Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jun 20, 2023 11:14am
208 Views
Post# 35505243

RE:RE:RE:Press Release

RE:RE:RE:Press ReleaseIf he's a con man, as you say, then he has been given free reign by...

Bihl (CoB), Walker (the EAA inventor, past CEO, major SH, etc.), Birch Hill, and Toray, amoungst others....(see AGM voting results)

Imagine that !?

Are they all in on the con?

Did he dupe Baxter as well ? And Kellum?

I suppose, in your eyes,  Ronco et al, Euphas 2, and hundreds of Trials/Studies and papers on PMX including many meta-analyses, are all in on the con as well?


Again...I'm not a fan of Seto's profile or accomplishments during his tenure, relative to his compensation package...(and the DIMI expectation management 2021-2022 was laughable)


however...

regarding PMX & EAA (the crown jewels) the most damage he could do, IMO, is to allow for too much dilution (e.g.caused by further Trial completion delays, underselling the story, emphasizing the wrong markets)

The endgame is almost certain. In that sense, a dog with a note, should be able to bring this one home for a hansome profit for most SHers.

MM
<< Previous
Bullboard Posts
Next >>